Company News
2024.10.30
Dx&Vx, 'Room temperature ultra-long-term stockpiling mRNA vaccine material and mass production process technology development' selected as national projec
DXVX announced on the 30th its selection as a co-research institution for Korea's first ARPA-H project, "STOREx: Stockpile Technology to Omit Repeated Entity for Vx," focused on developing materials and production technology for the long-term room-temperature storage of mRNA vaccines. DXVX will be responsible for verifying the genomic integrity of the mRNA vaccine technology and leading its commercialization.
The Korean ARPA-H project, spearheaded by the Korea Health Industry Development Institute (KHIDI), is an innovative research initiative aimed at addressing major healthcare challenges, modeled after the U.S. government’s ARPA-H project in the healthcare sector.
Under this project, DXVX will contribute to the development of technology for long-term room-temperature preservation of mRNA vaccines to enhance national health security and ensure rapid pandemic response. The project is led by Professor Seung-Soo Oh from the Department of Materials Science and Engineering at Pohang University of Science and Technology (POSTECH), with DXVX, Korea University, Gwangju Institute of Science and Technology, Ewha Womans University, and Seoul Asan Medical Center participating as co-research institutions. Following the completion of technology development, DXVX will lead commercialization efforts.
The project has secured a research fund totaling 8.5 billion KRW over five years, allocated as 1.5 billion KRW for the initial phase, 5 billion KRW for the second, and 2 billion KRW for the third.
Previously, DXVX collaborated with POSTECH on mRNA vaccine development, including lipid nanoparticle (LNP) technology. In this project, DXVX assumes a pivotal role in verifying and commercializing the mRNA vaccine technology. Current commercial mRNA vaccines require ultra-low-temperature storage and have limited shelf lives, creating challenges in distribution and storage. The development of technology for long-term, room-temperature storage and large-scale production of mRNA vaccines is a complex, high-cost endeavor, but DXVX's contributions are anticipated to significantly bolster national healthcare stability and secure vaccine sovereignty.
DXVX CEO Kwon Kyu-chan commented, “Leveraging our accumulated expertise in precision medicine, including genomic integrity analysis technology, we are taking a central role in this project. The development of technology for long-term room-temperature preservation and large-scale production of mRNA vaccines represents a groundbreaking innovation with the potential to reshape the entire mRNA vaccine market. We are committed to commercializing this technology, positioning ourselves to lead domestic vaccine development and setting new standards in the global mRNA vaccine platform market.”
The Korean ARPA-H project, spearheaded by the Korea Health Industry Development Institute (KHIDI), is an innovative research initiative aimed at addressing major healthcare challenges, modeled after the U.S. government’s ARPA-H project in the healthcare sector.
Under this project, DXVX will contribute to the development of technology for long-term room-temperature preservation of mRNA vaccines to enhance national health security and ensure rapid pandemic response. The project is led by Professor Seung-Soo Oh from the Department of Materials Science and Engineering at Pohang University of Science and Technology (POSTECH), with DXVX, Korea University, Gwangju Institute of Science and Technology, Ewha Womans University, and Seoul Asan Medical Center participating as co-research institutions. Following the completion of technology development, DXVX will lead commercialization efforts.
The project has secured a research fund totaling 8.5 billion KRW over five years, allocated as 1.5 billion KRW for the initial phase, 5 billion KRW for the second, and 2 billion KRW for the third.
Previously, DXVX collaborated with POSTECH on mRNA vaccine development, including lipid nanoparticle (LNP) technology. In this project, DXVX assumes a pivotal role in verifying and commercializing the mRNA vaccine technology. Current commercial mRNA vaccines require ultra-low-temperature storage and have limited shelf lives, creating challenges in distribution and storage. The development of technology for long-term, room-temperature storage and large-scale production of mRNA vaccines is a complex, high-cost endeavor, but DXVX's contributions are anticipated to significantly bolster national healthcare stability and secure vaccine sovereignty.
DXVX CEO Kwon Kyu-chan commented, “Leveraging our accumulated expertise in precision medicine, including genomic integrity analysis technology, we are taking a central role in this project. The development of technology for long-term room-temperature preservation and large-scale production of mRNA vaccines represents a groundbreaking innovation with the potential to reshape the entire mRNA vaccine market. We are committed to commercializing this technology, positioning ourselves to lead domestic vaccine development and setting new standards in the global mRNA vaccine platform market.”